1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

KPTI
Karyopharm Therapeutics Inc.US flagNASDAQ Global Select
0.35
USD
-0.04
- -
7.85MMarket Cap
Karyopharm Therapeutics Inc.
KPTI
(NASDAQ Global Select)

Recent

price

0.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.23
0.97
0.96
0.11
0.11
0.06
0.52
8.01
9.9
22.5
41.84
28.78
19.17
17.88
13.36
7.57
Revenue per Share
-15.79
-24.33
-83.92
-36.51
-49.77
-43.8
-42.15
-47.11
-48.32
-40.87
-24.75
-30.28
-18.79
-9.41
-17.93
-11.6
Basic EPS, GAAP
-13.66
-23.93
-75.02
-26.15
-40.19
-33.76
-24.11
-42.64
-46.25
-33.39
-22.5
-27.42
-12.17
-15.71
-6.89
-3.37
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-6.61
-14.55
78.55
94.86
82.96
58.1
39.21
45.17
11.42
10.26
-15.78
-2.21
-17.78
-22.11
-16
-14.56
Book Value per Share
-6.61
-14.55
78.55
94.86
82.96
58.1
39.21
45.17
11.42
10.26
-15.78
-2.21
-17.78
-22.11
-16
-14.56
Tangible Book Value per Share
1
1
- -
2
2
3
3
4
4
5
5
5
8
8
11
19
Basic Weighted Avg Shares
- -
1
- -
- -
- -
- -
2
30
41
108
210
157
146
145
146
147
Sales/Revenue/Turnover
-6,783.55
-2,506.31
-8,772.61
-33,120.52
-47,630.4
-71,903.9
-8,133.21
-592.97
-462.85
-159
-46.84
-90.53
-88.71
-82.24
-62.1
-56.17
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
1
1
1
1
- -
- -
- -
Depreciation Expense
-10
-16
-34
-76
-118
-110
-129
-178
-200
-196
-124
-165
-143
-76
-196
-225
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-6,783.55
-2,505.99
-8,771.83
-33,090.39
-47,272.4
-71,153.9
-8,036.39
-588.1
-488.08
-181.59
-59.14
-105.23
-97.99
-52.62
-134.21
-153.28
Profit Margin (%)
5
-1
155
195
162
115
99
288
232
216
202
284
164
64
11
-28
Working Capital
- -
- -
- -
- -
- -
- -
- -
103
123
129
178
176
174
170
212
215
LT Debt
-13
-28
155
207
198
162
129
183
50
51
-80
-17
-136
-186
-293
-330
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-41.9
-58.34
-60.77
-88.43
-114.13
-171.36
-391.29
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
22
33
41
LT Borrowings
206
192
210
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
23
23
Market Capitalization
135
126
222

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
103
126
106
Cash, Cash Equivalents & STI
64
91
65
Accounts Receivable, Net
26
23
30
Inventories
4
4
4
Total Current Liabilities
92
117
134
Payables & Accruals
64
81
86
ST Debt
22
33
41
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.69%
95.02%
57.47%
Free Cash Flow
5.86%
-7.67%
-40.95%
Net Income, GAAP
15.19%
18.58%
156.52%
Sales/Revenue/Turnover
295.5%
12.39%
0.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33
43
39
31
145
2025
30
38
44
34
146
2026
35
33
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-4.85
2.95
-3.85
-3.67
-9.41
2025
-2.77
-4.32
-3.82
-5.71
-17.93
2026
-1.02
-2.32
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Halozyme Therapeutics, Inc. (0J2O.L)
Gelesis Holdings, Inc. (GLSHQ)
Graybug Vision, Inc. (GRAY)
Cellectar Biosciences, Inc. (CLRB)
Impel Pharmaceuticals Inc. (IMPL)
Stemcell Holdings, Inc. (STMM)
Business
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapies targeting nuclear export dysregulation for cancer and other diseases; its lead product, XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, is approved by the FDA, European Commission, UK Medicines and Healthcare products Regulatory Agency, and Israeli Ministry of Health for multiple myeloma and diffuse large B-cell lymphoma in combination with other agents, and marketed as NEXPOVIO in Europe and the UK; the company advances a pipeline of SINE compounds including eltanexor and four clinical-stage drug candidates for hematologic malignancies and solid tumors such as endometrial cancer and myelofibrosis. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm maintains operations across the United States, Europe (with presence in Switzerland and Germany), Israel, and China, serving oncology patients through commercial activities, clinical trials, and patient support programs like KaryForward. Recent developments include significant refinancing transactions in May 2024 with HealthCare Royalty and convertible note holders, comprising a $100 million senior secured term loan and amended royalty agreements extending debt maturities to 2028-2029 to fund Phase 3 readouts expected in 2025; a collaboration with Bristol Myers Squibb to evaluate selinexor with mezigdomide in relapsed/refractory multiple myeloma; and Q3 2025 U.S. net product revenue of $32 million for XPOVIO, up 8.5% year-over-year, alongside ongoing inducement grants under its 2022 stock plan.

Company News

Company News APIChatGPT

  • prnewswire.com

    Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • defenseworld.net

    Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)

  • prnewswire.com

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • gurufocus.com

    Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

  • prnewswire.com

    Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • seekingalpha.com

    Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • zacks.com

    Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

  • prnewswire.com

    Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • prnewswire.com

    Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  • prnewswire.com

    Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • prnewswire.com

    Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

  • prnewswire.com

    Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer